Pharmaceutical Life Cycle Management: Updates on Navigating the IP, FDA and Antitrust Terrain

Events / Wednesday, April 5, 2017

There’s been a sea change in the political climate. The regulatory forecast is still uncertain, and pharmaceutical evolution continues to develop.

Efforts to extend the life cycle of pharmaceutical products frequently involve innovations and improvements in product design, formulation, route of administration and treatment indications. In addition, negotiation of agreements with competitors, including generic and biosimilar manufacturers, is frequently employed as part of a life cycle management strategy. However, recent changes in patent, regulatory and antitrust laws have introduced considerable complexity and risk into these strategies.

Be prepared for what the next year may bring by attending this important webinar, which brings together our experienced professionals to talk about these issues and approaches for successful pharmaceutical life cycle management.

  • Carl W. Hittinger, Partner, Philadelphia
  • Lee H. Rosebush, Partner, Washington, D.C.
  • Lance L. Shea, Partner, Washington, D.C.
  • S. Maurice Valla, Partner, Philadelphia


In The Blogs

Previous Next
Health Law Update
Senate Democrats recently introduced the Stop Price Gouging Act
February 15, 2019
Senate Democrats recently introduced the Stop Price Gouging Act (S. 378), which seeks to place an excise tax on pharmaceutical companies in proportion to price spikes on prescription drugs. The bill generally requires a company to justify...
Health Law Update
PE Investment in Physician Practice Management ? What's to Come in 2019?
By Jessie M. Gabriel, Adam D. Gale, Laurice Rutledge Lambert, Jennifer P. Whitton
February 13, 2019
Private equity (PE) investors entered the physician practice management (PPM) market in 2011, and eight years later the PPM sector continues to be a ripe middle market for PE investors looking to diversify their portfolios. However, as the...
IP Intelligence: Insight on Intellectual Property
Federal Circuit holds that claims directed to diagnosing neurotransmission or developmental disorders are invalid for failing to recite patent eligible subject matter
By Ronald C. Kern Jr., Ph.D.
February 11, 2019
In Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC,[1] the Federal Circuit affirmed the district court’s ruling that claims covering methods for diagnosing neurological disorders by detecting autoantibodies are directed to a...
Health Law Update
The Use of Smart Speakers in Healthcare
January 31, 2019
Smart speakers are voice-activated, internet-connected devices with an integrated virtual assistant that can answer questions, follow instructions and control other smart devices. Nearly one in five U.S. adults has access to a smart...
IP Intelligence: Insight on Intellectual Property
Supreme Court Unshrouds the ‘On Sale' Bar as Applied to Secret Sales
By Erin C. Caldwell
January 25, 2019
This week, the Supreme Court issued a decision holding that a secret sale qualifies as prior art. At issue was whether the America Invents Act (AIA) changed the “on sale” bar to patentability to exempt secret sales as prior art.[1] The...